. Author manuscript; available in PMC: 2014 Jul 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2013 Apr 10;19(7):1033–1039. doi: 10.1016/j.bbmt.2013.04.005

Table 5.

Incidences of sinusoidal obstruction syndrome and liver disease of unknown etiology among patients conditioned with ^TBU/CY vs. CY/^TBU.

	CY/^TBU (n=51)	^TBU/CY (n=271)

Myelofibrosis	20	33
No liver disease	17 (85%)	19 (58%)
LDUE	3 (15%)	4 (12%)
SOS	0(0%)	10 (30%)
Mild	0	2
Moderate	0	6
Severe	0	2

AML/MDS	31	238
No liver disease	26 (84%)	203 (85%)
LDUE	3 (10%)	13 (5%)
SOS	2 (6%)	22 (9%)
Mild	0	3
Moderate	2	10
Severe	0	9

Abbreviations: CY, cyclophosphamide; ^TBU, targeted busulfan; LDUE, liver disease of unknown etiology; SOS, sinusoidal obstruction syndrome; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.